Drug name - Aplenzin

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7569610 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7585897 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7572935 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7662407 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7645802 BAUSCH Bupropion hydrobromide and therapeutic applications Jun, 2026

(3 years from now)

US7671094 BAUSCH Bupropion hydrobromide and therapeutic applications Jun, 2026

(3 years from now)

US7649019 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7241805 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

Drugs and Companies using BUPROPION HYDROBROMIDE ingredient

Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
174MG TABLET, EXTENDED RELEASE;ORAL Prescription
348MG TABLET, EXTENDED RELEASE;ORAL Prescription
522MG TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.